糖尿病心肌病发病机制的研究进展

doi:10.19586/j.2095-2341.2021.0023

生物技术进展 ›› 2021, Vol. 11 ›› Issue (6): 700-704.DOI: 10.19586/j.2095-2341.2021.0023

糖尿病心肌病发病机制的研究进展

廖敏(), 杨洛, 王珍, 郝亚荣()

武汉大学人民医院老年病科，武汉 430060

收稿日期:2021-03-01 接受日期:2021-04-14 出版日期:2021-11-25 发布日期:2021-11-26
通讯作者: 郝亚荣
作者简介:廖敏 E-mail： 1287144956@qq.com；
基金资助:
湖北省自然科学基金项目(2016CFB673)

Research Progress on the Pathogenesis of Diabetic Cardiomyopathy

Min LIAO(), Luo YANG, Zhen WANG, Yarong HAO()

Department of Geriatrics，Renmin Hospital of Wuhan University，Wuhan 430060，China

Received:2021-03-01 Accepted:2021-04-14 Online:2021-11-25 Published:2021-11-26
Contact: Yarong HAO

摘要/Abstract

摘要：

糖尿病心肌病（diabetic cardiomyopathy, DCM）是一种特殊类型的心脏疾病，在一定程度上增加了糖尿病患者发生心力衰竭的风险，也是糖尿病患者死亡的主要原因之一。DCM的发病机制涉及多个方面，心肌细胞代谢紊乱（如高血糖和胰岛素抵抗）、心肌炎症和纤维化是DCM发病的基础，这些因素单独或联合作用于DCM的发生和发展。目前临床上尚无根治DCM的有效药物，研究疾病的发病机制在开发靶向治疗药物中具有重要意义。主要对当前DCM发病机制的研究进展展开综述，以期为DCM的早期预防和治疗提供理论基础。

关键词: 糖尿病心肌病, 心力衰竭, 高血糖, 胰岛素抵抗

Abstract:

Diabetic cardiomyopathy （DCM） is a special type of heart disease， which increases the risk of heart failure in diabetic patients to some extent and is also one of the main causes of death in diabetic patients. The pathogenesis of DCM involves many aspects. Myocardial cell metabolic disorders （such as hyperglycemia and insulin resistance）， myocardial inflammation and fibrosis are the basis of the pathogenesis of DCM， and these factors act on the occurrence and development of DCM individually or in combination. At present， there is no effective drug for the radical cure of DCM in clinical practice， and the study of the pathogenesis of DCM is of great significance in the development of targeted therapy drugs. The pathogenesis of DCM was mainly reviewed in order to provide theoretical basis for the early prevention and treatment of DCM.

Key words: diabetic cardiomyopathy, heart failure, hyperglycemia, insulin resistance

中图分类号:

R587.2

廖敏, 杨洛, 王珍, 郝亚荣. 糖尿病心肌病发病机制的研究进展[J]. 生物技术进展, 2021, 11(6): 700-704.

Min LIAO, Luo YANG, Zhen WANG, Yarong HAO. Research Progress on the Pathogenesis of Diabetic Cardiomyopathy[J]. Current Biotechnology, 2021, 11(6): 700-704.

图/表 1

参考文献 39

1	SAEEDI P, PETERSOHN I, SALPEA P, et al.. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition[J/OL]. Diabetes Res. Clin. Pract., 2019,157: 107843[2021-11-01]..
2	RUBLER S, DLUGAS J, YUCEOGLU Y Z, et al.. New type of cardiomyopathy associated with diabetic glomerulosclerosis[J]. Am. J. Cardiol., 1972,30(6): 595-602.
3	ALONSO N, MOLINER P, MAURICIO D. Pathogenesis, clinical features and treatment of diabetic cardiomyopathy[J]. Adv. Exp. Med. Biol., 2018,1067: 197-217.
4	MURTAZA G, VIRK H U H, KHALID M, et al.. Diabetic cardiomyopathy-a comprehensive updated review[J]. Prog. Cardiovasc. Dis., 2019,62(4): 315-326.
5	LIU F H, SONG R S, FENG Y Q, et al.. Upregulation of MG53 induces diabetic cardiomyopathy through transcriptional activation of peroxisome proliferation-activated receptor α[J]. Circulation, 2015,131(9): 795-804.
6	LEE T W, BAI K J, LEE T I, et al.. PPARs modulate cardiac metabolism and mitochondrial function in diabetes[J/OL]. J. Biomed. Sci., 2017,24(1):5[2021-11-01]. .
7	EVANGELISTA I, NUTI R, PICCHIONI T, et al.. Molecular dysfunction and phenotypic derangement in diabetic cardiomyopathy[J/OL]. Int. J. Mol. Sci., 2019,20(13): 3264[2021-11-01]. .
8	RIEHLE C, ABEL E D. Insulin signaling and heart failure[J]. Circ. Res., 2016,118(7): 1151-1169.
9	ADAMEOVA A, DHALLA N S. Role of microangiopathy in diabetic cardiomyopathy[J]. Heart Fail. Rev., 2014,19(1): 25-33.
10	赵航, 冯景辉, 吴秀萍. 糖尿病心肌病发病机制的研究进展[J]. 国际心血管病杂志, 2016,43(01): 16-18.
11	JIA G H, DEMARCO V G, SOWERS J R. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy[J]. Nat. Rev. Endocrinol., 2016,12(3): 144-153.
12	SZABLEWSKI L. Glucose transporters in healthy heart and in cardiac disease[J]. Int. J. Cardiol., 2017,230: 70-75.
13	王瑞瑶, 霍梦露, 李超, 等. 小檗碱对高糖诱导心肌细胞AMPK-AS160-GLUT4通路的调节及保护作用[J]. 中国临床保健杂志, 2020,23(02): 241-246.
14	SHAH M S, BROWNLEE M. Molecular and cellular mechanisms of cardiovascular disorders in diabetes[J]. Circ. Res., 2016,118(11): 1808-1829.
15	ZL0BINE I, GOPAL K, USSHER J R. Lipotoxicity in obesity and diabetes-related cardiac dysfunction[J]. Biochim. Biophys. Acta, 2016,1861(10): 1555-1568.
16	AROW M, WALDMAN M, YADIN D, et al.. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy[J/OL]. Cardiovasc. Diabetol., 2020,19(1): 7[2021-11-01]. .
17	FARIA A, PERSAUD S J. Cardiac oxidative stress in diabetes: mechanisms and therapeutic potential[J]. Pharmacol. Ther., 2017,172: 50-62.
18	RADA P, GONZÁLEZ-RODRÍGUEZ Á, GARCÍA-MONZÓN C, et al.. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?[J/OL]. Cell Death Dis., 2020,11(9): 802[2021-11-01]. .
19	YAZICI D, SEZER H. Insulin resistance, obesity and lipotoxicity[J]. Adv. Exp. Med. Biol., 2017,960: 277-304.
20	JIA G H, WHALEY-CONNELL A, SOWERS J R. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease[J]. Diabetologia, 2018,61(1): 21-28.
21	WU H K, ZHANG Y, CAO C M, et al.. Glucose-sensitive myokine/cardiokine MG53 regulates systemic insulin response and metabolic homeostasis[J]. Circulation, 2019,139(7): 901-914.
22	陶静, 钱润芳, 陈俊婷, 等. 下调CD36在心肌中的表达对肥胖小鼠心肌纤维化和凋亡的影响[J]. 医学研究杂志, 2019,48(09): 25-30.
23	AGUER C, MERCIER J, MAN C Y, et al.. Intramyocellular lipid accumulation is associated with permanent relocation ex vivo and in vitro of fatty acid translocase (FAT)/CD36 in obese patients[J]. Diabetologia, 2010,53(6): 1151-1163.
24	YU Q L, VAZQUEZ R, ZABADI S, et al.. T-lymphocytes mediate left ventricular fibrillar collagen cross-linking and diastolic dysfunction in mice[J]. Matrix Biol., 2010,29(6): 511-518.
25	WANG S Y, ZHAO X X, YANG S, et al.. Salidroside alleviates high glucose-induced oxidative stress and extracellular matrix accumulation in rat glomerular mesangial cells by the TXNIP-NLRP3 inflammasome pathway[J]. Chem. Biol. Interact., 2017,278: 48-53.
26	DENG L, CHEN X X, ZHONG Y, et al.. Activation of TGR5 partially alleviates high glucose-induced cardiomyocyte injury by inhibition of inflammatory responses and oxidative stress[J]. Oxid. Med. Cell. Longev., 2019,2019: 1-11.
27	WANG Y, QIAN Y Y, FANG Q L, et al.. Saturated palmitic acid induces myocardial inflammatory injuries through direct binding to TLR4 accessory protein MD2[J/OL]. Nat. Commun., 2017,8(1):13997[2021-11-01]. .
28	林中民, 陈国荣, 张泉波, 等. 髓样分化蛋白2基因沉默对高糖诱导的大鼠心肌细胞增殖抑制、凋亡及炎症反应的影响[J]. 中国应用生理学杂志, 2019,35(03): 273-279.
29	RUSSO I, FRANGOGIANNIS N G. Diabetes-associated cardiac fibrosis: cellular effectors, molecular mechanisms and therapeutic opportunities[J]. J. Mol. Cell. Cardiol., 2016,90: 84-93.
30	ZHANG Y, WANG J H, ZHANG Y Y, et al.. Deletion of interleukin-6 alleviated interstitial fibrosis in streptozotocin-induced diabetic cardiomyopathy of mice through affecting TGFbeta1 and miR-29 pathways[J/OL]. Sci. Rep., 2016,6: 23010[2021-11-01]. .
31	ADEBIYI O A, ADEBIYI O O, OWIRA P M. Naringin reduces hyperglycemia-induced cardiac fibrosis by relieving oxidative stress[J/OL]. PLoS ONE, 2016,11(3): e0149890[2021-11-01]. .
32	FU S, LI Y L, WU Y T, et al.. Icariside II improves myocardial fibrosis in spontaneously hypertensive rats by inhibiting collagen synthesis[J]. J. Pharm. Pharmacol., 2020,72(2): 227-235.
33	LIU J C, WANG F, XIE M L, et al.. Osthole inhibits the expressions of collagen I and III through Smad signaling pathway after treatment with TGF-β1 in mouse cardiac fibroblasts[J]. Int. J. Cardiol., 2017,228: 388-393.
34	MENG S Y, YANG F, WANG Y Q, et al.. Silymarin ameliorates diabetic cardiomyopathy via inhibiting TGF-β1/Smad signaling[J]. Cell Biol. Int., 2019,43(1): 65-72.
35	GBR A A, ABDEL B N A, MOHAMED E A, et al.. Cardioprotective effect of pioglitazone and curcumin against diabetic cardiomyopathy in type 1 diabetes mellitus: impact on CaMKII/NF-κB/TGF-β1 and PPAR-γ signaling pathway[J]. Naunyn. Schmied. Arch. Pharmacol., 2021,394(2): 349-360.
36	YAN X L, WANG Y Y, YU Z F, et al.. Peroxisome proliferator-activated receptor-gamma activation attenuates diabetic cardiomyopathy via regulation of the TGF-β/ERK pathway and epithelial-to-mesenchymal transition[J]. Life Sci., 2018,213: 269-278.
37	LI G H, XING W J, ZHANG M, et al.. Antifibrotic cardioprotection of berberine via downregulating myocardial IGF-1 receptor-regulated MMP-2/MMP-9 expression in diabetic rats[J]. Am. J. Physiol. Heart Circ. Physiol., 2018,315(4): H802-H813.
38	WESTERMANN D, RUTSCHOW S, JÄGER S, et al.. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism[J]. Diabetes, 2007,56(3): 641-646.
39	谢发江, 蒋松辰, 高尚远, 等. 法舒地尔调控巨噬细胞极化改善糖尿病小鼠心肌纤维化[J]. 中国病理生理杂志, 2019,35(05): 881-888.

糖尿病心肌病发病机制的研究进展

Research Progress on the Pathogenesis of Diabetic Cardiomyopathy

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 39

相关文章 1

编辑推荐

Metrics

本文评价